Charles Keller, M.D.
Affiliations: | Children's Cancer Therapy Development Institute |
Google:
"Charles Keller"Mean distance: (not calculated yet)
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zhang H, Qi L, Du Y, et al. (2020) Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma. Cancers. 12 |
| Harrold AP, Cleary MM, Bharathy N, et al. (2020) In vitro benchmarking of NF-κB inhibitors. European Journal of Pharmacology. 172981 |
| Kats D, Ricker CA, Berlow NE, et al. (2019) Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget. 10: 6403-6417 |
| Yohe ME, Heske CM, Stewart E, et al. (2019) Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatric Blood & Cancer. e27869 |
| Berlow NE, Rikhi R, Geltzeiler M, et al. (2019) Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. Bmc Cancer. 19: 593 |
| Bharathy N, Berlow NE, Wang E, et al. (2019) Preclinical rationale for entinostat in embryonal rhabdomyosarcoma. Skeletal Muscle. 9: 12 |
| Wei Q, Ramsey SA, Larson MK, et al. (2019) Elucidating the transcriptional program of feline injection-site sarcoma using a cross-species mRNA-sequencing approach. Bmc Cancer. 19: 311 |
| Zhang H, Qi L, Du Y, et al. (2019) TMOD-21. TARGETING ANAPLASTIC MENINGIOMA WITH PANOBINOSTAT IN PATIENT-DERIVED ORTHOTOPIC XENOGRAFT (PDOX) MODELS DERIVED FROM A MATCHING PAIR OF PRIMARY AND RECURRENT TUMORS Neuro-Oncology. 21: vi267-vi267 |
| Bharathy N, Berlow NE, Wang E, et al. (2018) The HDAC3-SMARCA4-miR-27a axis promotes expression of the fusion oncogene in rhabdomyosarcoma. Science Signaling. 11 |
| Malempati S, Chang BH, Reid JM, et al. (2018) ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors. Journal of Clinical Oncology. 36: 10556-10556 |